Evidence map›Paper›PMID 32090640›Full record

ArticleDrug delivery2020

Formation of inclusion complex of enrofloxacin with 2-hydroxypropyl-

Yili Ding, Yuchang Pang, Chamakura V N S Vara Prasad, Bingyun Wang

Open access · goldAbstract readComparative Study
In one paragraph

Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Randomly MethylatedMolecules (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yili DingLife Science Department, Foshan University, Foshan, P. R. China.
Yuchang PangLife Science Department, Foshan University, Foshan, P. R. China.
Chamakura V N S Vara PrasadDas Pharma, Kakinada, India.
Bingyun WangLife Science Department, Foshan University, Foshan, P. R. China.
Foshan University · CNJawaharlal Nehru Technological University, Kakinada · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enrofloxacin, a third-generation fluoroquinolone, is a broad-spectrum antimicrobial drug against a lot of veterinary bacterial diseases. However, bactericidal activity of enrofloxacin is concentration-dependent and its poor aqueous solubility and bitter taste limit its development and application. Meanwhile, 2-hydroxypropyl-

Indexed as

2-Hydroxypropyl-beta-cyclodextrinAnimalsAnti-Bacterial AgentsBiological AvailabilityDrug CarriersEnrofloxacinRatsSolubility2-Hydroxypropyl-beta-cyclodextrinAnti-Bacterial AgentsDrug CarriersEnrofloxacin2-hydroxypropyl-β-cyclodextrinEnrofloxacininclusion complexpharmaceutical propertiespreparation

Identifiers

PMID32090640
PMCPMC7057344
OpenAlexW3007580707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.